Pulse Biosciences (NASDAQ:PLSE) COO Liane Rae Teplitsky Purchases 1,034 Shares

Key Points

• Pulse Biosciences COO Liane Rae Teplitsky bought 1,034 shares at an average price of $48.35, investing nearly $50,000 and nearly doubling her direct ownership to 2,070 shares. She also purchased 1,036 shares earlier in the week.
• PLSE shares fell 2.0% to $47.57, despite trading near its 52-week high of $50.90. The company reported a quarterly loss of $0.36 per share, worse than the expected $0.29 loss, alongside revenue below estimates.
• Analyst sentiment remains mixed but leans positive, with four Buy ratings and one Sell rating producing a “Moderate Buy” consensus and a $45.25 average price target. Institutional investors own approximately 76.95% of the company.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) COO Liane Rae Teplitsky acquired 1,034 shares of the stock in a transaction on Friday, August 28th. The shares were bought at an average cost of $48.35 per share, for a total transaction of $49,993.90. Following the purchase, the chief operating officer directly owned 2,070 shares of the company's stock, valued at $100,084.50. The trade was a 99.81% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Liane Rae Teplitsky also recently made the following trade(s):

• On Wednesday, August 26th, Liane Rae Teplitsky bought 1,036 shares of Pulse Biosciences stock. The stock was bought at an average cost of $48.23 per share, with a total value of $49,966.28.

Pulse Biosciences Stock Down 2.0%

Shares of PLSE traded down $0.99 during midday trading on Friday, reaching $47.57. The company had a trading volume of 262,703 shares, compared to its average volume of 406,808. Pulse Biosciences, Inc has a 1-year low of $12.56 and a 1-year high of $50.90. The firm has a 50 day simple moving average of $35.38 and a 200-day simple moving average of $27.00. The stock has a market cap of $3.29 billion, a PE ratio of -40.31 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. As a group, sell-side analysts anticipate that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in shares of Pulse Biosciences during the first quarter valued at about $323,000. Creative Planning increased its holdings in Pulse Biosciences by 26.3% in the 2nd quarter. Creative Planning now owns 18,971 shares of the company's stock valued at $286,000 after purchasing an additional 3,951 shares during the last quarter. Legal & General Group Plc increased its holdings in Pulse Biosciences by 57.7% in the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company's stock valued at $338,000 after purchasing an additional 8,197 shares during the last quarter. Norges Bank purchased a new stake in Pulse Biosciences in the second quarter valued at approximately $302,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Pulse Biosciences in the second quarter valued at approximately $158,000. Hedge funds and other institutional investors own 76.95% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Oppenheimer reaffirmed an "outperform" rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Wall Street Zen cut Pulse Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Mizuho set a $45.00 price objective on Pulse Biosciences in a research report on Monday, August 10th. Finally, Needham & Company LLC assumed coverage on Pulse Biosciences in a research note on Monday, August 17th. They set a "buy" rating and a $58.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $45.25.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source